13 results about "CCR1" patented technology

The invention discloses a method for analyzing a mechanism of treating leucopenia by using a Shengbai oral liquid by using a network pharmacology mode, and the method is based on an HITS algorithm, and identifies key regulation and control nodes through hub and authority scores of nodes. An analysis result shows that PPBP, ALOXE3 and CCR1 are hub genes ranked in the first three, and PPBP not only has the highest hub score, but also shows the most significant expression change. In a bone marrow microenvironment, PPBP / CXCL7 may affect differentiation and maturation of hematopoietic stem cells and promote generation of specific types of leukocytes.

A monoclonal antibody is provided which binds to a human CC chemokine receptor 1 (CCR1) and inhibits activation of the human CCR1, or an antibody fragment thereof. The monoclonal antibody binds to an extracellular region of a human CCR1 and inhibits activation of the human CCR1 by a human CC chemokine ligand 15 (CCL15). An antibody fragment thereof, a hybridoma producing the antibody, a nucleic acid having a nucleotide sequence encoding the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment using the hybridoma or the transformant cell; a therapeutic agent and a diagnostic agent containing the antibody or the antibody fragment, and a method for treating and diagnosing a CCR1-related disease using the antibody or the antibody fragment are also provided.

The present invention relates to: a composition for diagnosing colorectal cancer, comprising a substance capable of measuring the relative expression levels of CCR1, CD177, DLG5, EPCAM, ERBB2, FCGR1A, FOXA2, GK, KRT19, KRT73, MKI67, MPO, MUC1, NME1, NPTN, NQO2, SH2D1B, SNAI2, TERT, TUG1, and VIM genes or proteins encoded by the genes; a kit for diagnosing colorectal cancer, comprising the composition; and a method for diagnosing colorectal cancer by using the kit.

This invention provides a method for screening peptides that specifically target T cells, comprising providing T cells having a subset selected from CD1, CD2, CD3, CD4, CD5, CD7, CD8, CD16, CD25, CD26, CD27, CD28, CD30, CD38, CD39, CD40L, CD44, CD45, CD62L, CD69, CD73, CD80, CD83, CD86, CD95, CD103, CD119, CD126, CD150, CD152 (CTLA-4), CD153, CD154 (CD40L) The T cells are labeled with at least one of the following surface antigen markers: CD161, CD183, CD223, CD254, CD275, CD45RA, CXCR3, CXCR5, FasL, IL18R1, CTLA-4, OX40, GITR, LAG3, ICOS, PD-1, leu-12, TCR, TLR1, TLR2, TLR3, TLR4, TLR6, NKG2D, CCR, CCR1, CCR2, CCR4, CCR6, and CCR7. The T cells are then contacted with a peptide display library, and target peptides that specifically bind to the T cells are screened therefrom.

The invention belongs to the technical field of biological medicines, and particularly relates to application of IAA in preparation of a medicine for preventing and treating atherosclerosis. Atherosclerosis is caused by excessive deposition of cholesterol, and IAA can significantly reduce formation of aorta and aortic sinus lipid plaques of atherosclerosis model mice by adjusting monocyte chemotactic and adhesion functions (specifically, down-regulating expression of chemotactic factors CCL2 and CXCL1, receptors CCR1 and CCR2, adhesion molecules ICAM1 and the like). An injection preparation is preferably selected as a medicine dosage form, the intervention dosage of IAA is 50 mg / kg, and the intervention time is 15 weeks. The new application of IAA in prevention and treatment of atherosclerosis is explored for the first time, the action mechanism of IAA is clear, the intervention effect is remarkable, and a new target spot and thought are provided for developing safe and effective medicines and means for preventing and treating atherosclerosis.

To provide acute myeloid leukemia antigen targets for chimeric receptors and methods of using same.SOLUTION: There is provided an isolated immunoresponsive cell comprising (a) a first chimeric receptor comprising an extracellular antigen-binding domain that binds to a first antigen, and (b) a second chimeric receptor comprising an extracellular antigen-binding domain that binds to a second antigen, wherein each antigen is selected from a group consisting of FLT3, CD33, CLEC12A, MS4A3, VSTM1, LAT2, MLC1, CD131, GAPT, PRAM1, SLC22A16, SLC17A9, SPNS3, ADGRE2, IL3RA, CD117, CD93, IL1RAP, CD244, CCR1, LILRB2, PIEZO1, CD38, EMB, MYADM, LILRA2, CD300LF, and CD70, and wherein the first antigen is different from the second antigen.SELECTED DRAWING: Figure 1

The invention discloses a CCL14 similar peptide for inhibiting tendon adhesion and application of the CCL14 similar peptide, and belongs to the technical field of biological medicines. The CCL14 similar peptide is obtained by carrying out amide condensation cyclization on an amino acid sequence as shown in SEQ ID NO: 4 and grafting a branched chain YHPSEC or HPSEC at the 12th site of the amino acid sequence as shown in SEQ ID NO: 4 through a disulfide bond. The similar peptide with the branched chain being YHPSEC or HPSEC is screened out and is tightly combined with CCR1 protein, meanwhile, the tendon adhesion resisting curative effect of the CCL14 similar peptide with the branched chain being YHPSEC on animals is similar to that of a CCL14 factor, and the CCL14 similar peptide can be used as a potential polypeptide medicine for treating tendon adhesion in a subcutaneous injection mode and has clinical transformation potential.

The invention relates to the technical field of biological medicines, in particular to application of a CCR1 / 5 inhibitor Met-RANTES in inhibition of pathological pain of trigeminal nerves. According to the invention, CCR1 / 5 is taken as a therapeutic target of chronic pain, and a medicine which is remarkable in analgesic effect, small in side effect and capable of relieving chronic pain and improving pain mood is developed by combining the pharmacological function of an inhibitor Met-RANTES of CCR1 / 5. The Met-RANTES inhibits a central nervous system chemokine receptor CCRR1 / 5 in a targeted manner in a regular nasal administration manner, so that pathological mechanical pain-sensitive response and accompanying negative emotion caused by chronic compression of trigeminal nerves can be remarkably relieved, and pain feeling is relieved. In addition, the analgesic effect of the drug combination of the Met-RANTES and the carbamazepine is more obvious than that of the drug combination of the Met-RANTES and the carbamazepine which are independently used. The nasal delivery mode enables the medicine to directly reach the central nervous system, and reduces side effects of the whole body.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a CCR1 targeting inhibitor in preparation of a medicine for treating lung cancer and bone metastasis cancer. It is verified for the first time that CCR1 + macrophage infiltration in bone metastasis microenvironments of mice and lung cancer patients is increased, lung cancer bone metastasis development can be inhibited by inhibiting CCR1 + macrophage infiltration, and a small molecule compound BX471 serves as a targeted CCR1 inhibitor and inhibits lung cancer bone metastasis by inhibiting CCR1 + macrophage infiltration and differentiation; a new target spot and a treatment strategy are provided for lung cancer bone metastasis.

Embodiments disclosed herein provide compositions for increasing CCL3 and / or CCL4 interactions with CCR5 and / or CCR1 to enhance an immune response. Applicants identified specific interactions between CD8+ T cells and inflammatory monocytes / macrophages that change during tumor progression from small to medium to large tumors. The ligands CCL3 and CCL4 are expressed in a specific subset of T cells (CD8+ PD-1+ TIM3+ T cells). The receptors CCR5 and CCR1 are expressed in inflammatory monocytes / macrophages. Modulation or maintenance of these interactions can allow enhanced immune responses for treating cancer, as well as for vaccination.

The invention belongs to the technical field of biology, and particularly relates to a serum-free culture solution for in-vitro maturation of oocytes and application of the serum-free culture solution. The invention relates to a CCR1 / CCR3 double-target small-molecule inhibitor. The preparation for in-vitro embryo production contains at least one of nerve axon protein family proteins and CCR1 / CCR3 double-target small-molecule inhibitors, so that the in-vitro maturation quality and efficiency of oocytes can be effectively improved, and further, xanthohumol in isopentenyl flavonoid compounds is added on the basis, so that the in-vitro maturation quality and efficiency of the oocytes can be effectively improved. The synergistic effect between the nerve axon protein family protein and the CCR1 / CCR3 double-target small-molecule inhibitor can be further enhanced, and the contents of lipid droplets and fatty acids of oocytes can be synergistically reduced, the endoplasmic reticulum stress can be relieved, the protein homeostasis can be improved, the anti-oxidation defense capability can be enhanced, and the like; the in-vitro maturation quality and the embryonic development potential of the oocyte are remarkably improved, and the application prospect is wide.

The invention provides application of a CCR1 antagonist in preparation of a medicine for improving the anti-tumor curative effect of CAR-T cells. The CCR1 antagonist (BX471) improves the tumor immune microenvironment by inhibiting the CCR1-mediated myeloid cell chemotaxis and related fibrosis signals, which is represented by reducing the inhibitory mononuclear / macrophage enrichment and matrix fibrosis level, so that the infiltration and effector functions of CAR-T on tumors are improved. In a mouse tumor model (including but not limited to B cell lymphoma and melanoma), BX471 is continuously given according to a preset treatment course after CAR-T infusion, and compared with single use of CAR-T, better tumor inhibition related indexes can be obtained; no obvious systemic toxic signal is seen under the tested dosage and treatment course. The invention provides a medication direction and an application basis for a tumor microenvironment facing immunological rejection caused by myelogenous enrichment.

The invention provides a CCR1 antagonist, or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment of pancreatic cancer, in particular a CCR1 antagonist, for example in combination with one or more further therapeutic agents effective as anti-tumour agents in the treatment of pancreatic cancer. Such an anti-tumour agent may be a chemotherapeutic agent selected from Gemcitabine, Fluorouracil (5-FU), Capecitabine, FOLFIRINOX (Leucovorin Calcium, Fluorouracil, Irinotecan Hydrochloride and Oxaliplatin), Nab-paclitaxel (Abraxane®) and combinations thereof. An immuno-oncology agent (e.g. a PD-1 inhibitor and / or a PD-L1 inhibitor) may also favourably be used with the CCR1 antagonist.